Ann: Neuren completes enrolment in Phelan-McDermid Phase 2 trial, page-2

So, if they commence the trial next week (and this is not confirmed, only enrolment is confirmed to be complete) then there is 4 weeks of baseline observation followed by 13 weeks of dosing, then a follow up observation 2 weeks after completion which takes it through until the end of the first week of November at the earliest. Then have all the data assessed and put into the appropriate P2 report format with results reported sometime in December. I’m looking forward to this. Meanwhile we have ROW, Day ur sales data, sale of the Trof priority review voucher as well as details on the other trials to keep the market interested.